Showing results (1171-1180 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|July 25, 2016
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumorsJ E Grilley-Olson, P L Bedard, A Fasolo, et al.
Investigational New Drugs|May 25, 2021
Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumorsRyan Ashkar, Darren R Feldman, Nabil Adra, et al.
Investigational New Drugs|May 25, 2021
Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenibJiunn-Chang Lin, Chien-Liang Liu, Yuan-Ching Chang, et al.
Investigational New Drugs|December 1, 1987
Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusionR Pazdur, G G Chabot, L H Baker
Investigational New Drugs|December 1, 1987
Phase II study of acivicin as a 72-hr continuous infusion in patients with untreated colorectal cancer. A National Cancer Institute of Canada Clinical Trials Group StudyE A Eisenhauer, J A Maroun, A L Fields, et al.
Investigational New Drugs|August 13, 2021
IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancerYuefeng Hu, Dong Liu, Peilin Cui, et al.
Investigational New Drugs|February 7, 2023
Anti-cancer activity of ultra-short single-stranded polydeoxyribonucleotidesAlexander S Vedenkin, Sergey V Stovbun, Alexander A Bukhvostov, et al.
Investigational New Drugs|March 8, 2023
A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid TumorsZhuang Kang, Shenglan Li, Yi Lin, et al.
Investigational New Drugs|July 30, 1999
Preclinical antitumor activity of XK469 (NSC 656889)P M LoRusso, R Parchment, L Demchik, et al.
Investigational New Drugs|July 30, 1999
Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrationsD R Shalinsky, J Brekken, H Zou, et al.
Pageof 372